Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)

scientific article published on 19 November 2018

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628) is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1110032962
P356DOI10.1186/S12885-018-5045-7
P932PMC publication ID6245867
P698PubMed publication ID30453910

P50authorNikolas von BubnoffQ87841821
P2093author name stringGabriele Ihorst
Jürgen Finke
Justus Duyster
Hartmut Bertz
Olga Grishina
Nadine Röthling
Robert Zeiser
P2860cites workThe pathophysiology of acute graft-versus-host disease.Q53676885
Steroid-Refractory Acute GVHD: Lack of Long-Term Improved Survival Using New Generation Anticytokine TreatmentQ58814216
Graft-versus-host diseaseQ83468020
Activity of therapeutic JAK 1/2 blockade in graft-versus-host diseaseQ87635679
Tyrosine kinase JAK1 is associated with the granulocyte-colony-stimulating factor receptor and both become tyrosine-phosphorylated after receptor activationQ24563701
Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantationQ24626051
International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium.Q30994673
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosisQ33391880
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosisQ33399980
Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage.Q34420372
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group reportQ34474243
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter surveyQ36862931
New perspectives on the biology of acute GVHD.Q37641063
When neutrophils meet T cells: beginnings of a tumultuous relationship with underappreciated potential.Q38179308
Jak1 plays an essential role for receptor phosphorylation and Stat activation in response to granulocyte colony-stimulating factorQ41099517
Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 productionQ41908710
A high risk of life-threatening infectious complications in mycophenolate mofetil treatment for acute or chronic graft-versus-host diseaseQ43136155
Advances in the clinical management of GVHD.Q43170920
Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatmentQ45164619
Acute Graft-versus-Host Disease - Biologic Process, Prevention, and TherapyQ49679320
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectmulticenter clinical trialQ6934595
ruxolitinibQ7383611
phase II clinical trialQ42824440
P304page(s)1132
P577publication date2018-11-19
P1433published inBMC CancerQ326300
P1476titleRuxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
P478volume18

Reverse relations

cites work (P2860)
Q92072381Emerging Topical and Systemic JAK Inhibitors in Dermatology
Q96690572Impaired Virus-Specific T Cell Responses in Patients with Myeloproliferative Neoplasms Treated with Ruxolitinib
Q92134267Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD
Q92327065Ruxolitinib treatment for acute gastrointestinal graft-versus-host disease caused by donor-derived CD19-Chimeric antigen receptor T-Cell infusion in a patient with B-ALL relapsed after Allo-HSCT
Q91522442Treatment and unmet needs in steroid-refractory acute graft-versus-host disease

Search more.